RadNet, Inc. (NASDAQ:RDNT) saw an uptick in trading volume on Monday . 906,931 shares changed hands during mid-day trading, an increase of 339% from the previous session’s volume of 206,648 shares.The stock last traded at $9.85 and had previously closed at $9.80.

A number of brokerages recently weighed in on RDNT. Zacks Investment Research cut shares of RadNet from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. BidaskClub raised shares of RadNet from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 24th. TheStreet raised shares of RadNet from a “c” rating to a “b-” rating in a research report on Thursday, August 24th. Finally, Jefferies Group LLC raised shares of RadNet from a “hold” rating to a “buy” rating and boosted their price target for the company from $7.00 to $12.00 in a research report on Tuesday, August 22nd.

The stock has a market capitalization of $469.10, a PE ratio of 32.83, a price-to-earnings-growth ratio of 3.31 and a beta of 0.87. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 7.88.

RadNet (NASDAQ:RDNT) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported $0.12 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.12. RadNet had a net margin of 1.21% and a return on equity of 23.73%. The firm had revenue of $227.60 million during the quarter, compared to analysts’ expectations of $232.84 million. During the same period in the previous year, the company earned $0.11 earnings per share. RadNet’s quarterly revenue was up 1.3% compared to the same quarter last year. analysts anticipate that RadNet, Inc. will post 0.35 EPS for the current fiscal year.

In other news, VP Mark Stolper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $10.19, for a total value of $101,900.00. Following the completion of the sale, the vice president now directly owns 145,319 shares of the company’s stock, valued at $1,480,800.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider John V. Crues sold 40,000 shares of the company’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $9.90, for a total transaction of $396,000.00. Following the completion of the sale, the insider now directly owns 623,781 shares of the company’s stock, valued at $6,175,431.90. The disclosure for this sale can be found here. Insiders sold 1,238,192 shares of company stock valued at $13,507,864 over the last ninety days. Corporate insiders own 9.36% of the company’s stock.

Several large investors have recently made changes to their positions in RDNT. Airain ltd purchased a new stake in shares of RadNet in the second quarter valued at about $100,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of RadNet in the second quarter valued at about $102,000. National Planning Corp raised its holdings in shares of RadNet by 9.8% in the second quarter. National Planning Corp now owns 16,796 shares of the medical research company’s stock valued at $132,000 after buying an additional 1,500 shares during the last quarter. American International Group Inc. raised its holdings in shares of RadNet by 7.0% in the first quarter. American International Group Inc. now owns 22,857 shares of the medical research company’s stock valued at $135,000 after buying an additional 1,500 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of RadNet by 5.9% in the first quarter. Bank of America Corp DE now owns 26,580 shares of the medical research company’s stock valued at $157,000 after buying an additional 1,477 shares during the last quarter. 50.32% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “RadNet, Inc. (RDNT) Sees Unusually-High Trading Volume” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/22/radnet-inc-rdnt-sees-unusually-high-trading-volume.html.

About RadNet

RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.

Receive News & Stock Ratings for RadNet Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet Inc. and related stocks with our FREE daily email newsletter.